Amyotrophic lateral sclerosis - The tools of the trait

Biotechnology Journal

Volumn 2, Issue 5, 2007, Pages 608-621

  Lederer, Carsten W ^a   Santama, Niovi ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

Author keywords

Amyotrophic lateral sclerosis; Motor neuron disease; Neurodegeneration

Indexed keywords

ADENOVIRUS VECTOR; ALSIN; ANTIINFLAMMATORY AGENT; ANTITOXIN; BIOLOGICAL MARKER; CELECOXIB; COPPER ZINC SUPEROXIDE DISMUTASE; GENE PRODUCT; GENE THERAPY AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; NEURITE PROMOTING FACTOR; NF HEAVY CHAIN; PROTEIN BCL XL; RILUZOLE; ROFECOXIB; SENATAXIN; SOMATOMEDIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CELL INTERACTION; DEGENERATIVE DISEASE; DRUG TARGETING; EXCITOTOXICITY; GENE EXPRESSION; GENE MUTATION; GENOMICS; GLIA CELL; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KINESIOTHERAPY; MOLECULAR DYNAMICS; MOTONEURON; MUTANT; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEOMICS; REVIEW; SOMATIC GENE THERAPY; STEM CELL TRANSPLANTATION; VIRAL GENE DELIVERY SYSTEM;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BIOLOGICAL MARKERS; BIOTECHNOLOGY; DRUG DELIVERY SYSTEMS; HUMANS; NERVE TISSUE PROTEINS;

ANIMALIA;

EID: 34249724387     PISSN: 18606768     EISSN: None     Source Type: Journal    
DOI: 10.1002/biot.200600247     Document Type: Review

References (146)

1. Rosen, D. R., Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 364, 362.
2. Deng, H. X., Hentati, A., Tainer, J. A., Iqbal, Z. et al., Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 1993, 261, 1047-1051.
3. Al-Chalabi, A., Leigh, P. N., Familial amotrophic lateral sclerosis and related motor neuron disorders, in: Emery, A. E. H. (Ed.), Neuromuscular Disorders: Clinical and Molecular Genetics, John Wiley & Sons, Chichester 2006, pp. 433-467.
4. Selverstone, V. J., Doucette, R. A., Zittin, P. S., Copper-Zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem. 2005, 74, 563-593.
5. Fischer, L. R., Culver, D. G., Tennant, P., Davis, A. A. et al., Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp. Neurol. 2004, 185, 232-240.
6. Stenson, P. D., Ball, E. V., Mort, M., Phillips, A. D. et al., Human gene mutation database (HGMD): 2003 Update. Hum. Mutat. 2003, 21, 577-581.
7. Figlewicz, D. A., Krizus, A., Martinoli, M. G., Meininger, V. et al., Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Mol. Genet. 1994, 3, 1757-1761.
8. Hadano, S., Hand, C. K., Osuga, H., Yanagisawa, Y. et al, A Gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 2001, 29, 166-173.
9. Yang, Y., Hentati, A., Deng, H. X., Dabbagh, O. et al., The gene encoding Alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 2001, 29, 160-165.
10. Chen, Y. Z., Bennett, C. L., Huynh, H. M., Blair, I. P. et al., DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 2004, 74, 1128-1135.
11. Trotti, D., Aoki, M., Pasinelli, P., Berger, U. V. et al., Amyotrophic lateral sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity. J. Biol Chem. 2001, 276, 576-582.
12. Nishimura, A. L., Mitne-Neto, M., Silva, H. C., Richieri-Costa, A. et al., A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 2004, 75, 822-831.
13. Greenway, M. J., Andersen, P. M., Russ, C, Ennis, S. et al., ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat. Genet. 2006, 38, 411-413.
14. Kawahara, Y., Ito, K., Sun, H., Aizawa, H. et al., Glutamate receptors: RNA editing and death of motor neurons. Nature 2004, 427, 801.
15. Steele, A. J., Al-Chalabi, A., Ferrante, K., Cudkowicz, M. E. et al., Detection of serum reverse transcriptase activity in patients With ALS and unaffected blood relatives. Neurology 2005, 64, 454-458.
16. Cox, P. A., Banack, S. A., Murch, S. J., Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc. Natl. Acad. Sci. USA 2003, 100, 13380-13383.
17. Stipa, G., Taiuti, R., de Scisciolo G., Arnetoli, G. et al., Sporadic amyotrophic lateral sclerosis as an infectious disease. A possible role of cyanobacteria? Med. Hypotheses 2006, 67, 1363-1371.
18. Miller, G., Neurodegenerative disease: Guam's deadly stalker: On the loose worldwide? Science 2006, 313, 428-431.
19. Carri, M. T., Grignaschi, G., Bendotti, C., Targets in ALS: Designing multidrug therapies. Trends Pharmacol. Sci. 2006, 27, 267-273.
20. Chio, A., Benzi, G., Dossena, M., Mutani, R. et al., Severely increased risk of amyotrophic lateral sclerosis among italian professional football players. Brain 2005, 128, 472-476.
21. Chevalier-Larsen, E., Holzbaur, E. L., Axonal transport and neurodegenerative disease. Biochim. Biophys. Acta 2006, 1762, 1094-1108.
22. Brooks, B. R., Diagnostic dilemmas in amyotrophic lateral sclerosis. J. Neurol. Sci. 1999, 165 Suppl 1, S1-S9.
23. Bowser, R., Cudkowicz, M., Kaddurah-Daouk, R., Biomarkers for amyotrophic lateral sclerosis. Expert. Rev. Mol. Diagn. 2006, 6, 387-398.
24. de Carvalho M., Costa, J., Swash, M., Clinical trials in ALS: A review of the role of clinical and neurophysiological measurements. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2005, 6, 202-212.
25. Armon, C., Brandstater, M. E., Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle Nerve 1999, 22, 1571-1575.
26. Great Lakes ALS Study Group, a comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 2003, 61, 1503-1507.
27. Kalra, S., Arnold, D., Neuroimaging in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2003, 4, 243-248.
28. McGeer, P. L., McGeer, E. G., Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002, 26, 459-470.
29. Bogdanov, M., Brown, R. H., Matson, W., Smart, R. et al., Increased oxidative damage to DNA in ALS patients. Free Radio. Biol Med. 2000, 29, 652-658.
30. Brockington, A., Wharton, S. B., Fernando, M., Gelsthorpe, C. H. et al., Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J. europathol. Exp. Neurol. 2006, 65, 26-36.
31. Lin, C. L., Bristol, L. A., Jin, L., Dykes-Hoberg, M. et al.. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998, 20, 589-602.
32. Maragakis, N. J., Dykes-Hoberg, M., Rothstein, J. D., Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann. Neurol. 2004, 55, 469-477.
33. Pantelidou, M., Zographos, S. E., Lederer, C. W., Kyriakides, T. et al., Differential expression of molecular motors in the motor cortex of sporadic ALS. Neurobiol. Dis. 2007, DOI: 10.1016/ j.nbd.2007.02.005.
34. Fathallah-Shaykh, H. M., Microarrays: Applications and pitfalls. Arch. Neurol. 2005, 62, 1669-1672.
35. Kapp, A. V., Jeffrey, S. S., Langerod, A., Borresen-Dale, A. L. et al., Discovery and validation of breast cancer subtypes. BMC Genomics 2006, 7, 231.
36. Tang, Y., Gilbert, D. L., Glauser, T. A., Hershey, A. D. et al., Blood gene expression profiling of neurologic diseases: a pilot microarray study. Arch. Neurol. 2005, 62, 210-215.
37. Borovecki, F., Lovrecic, L., Zhou, J., Jeong, H. et al., Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl. Acad. Sci. USA 2005, 102, 11023-11028.
38. Malaspina, A., Kaushik, N., de Belleroche J., Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA Arrays. J. Neurochem. 2001, 77, 132-145.
39. Jiang, Y. M., Yamamoto, M., Kobayashi, Y., Yoshihara, T. et al., Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann. Neurol. 2005, 57, 236-251.
40. Dangond, F., Hwang, D., Camelo, S., Pasinelli, P. et al., Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. Physiol. Genomics 2004, 16, 229-239.
41. Wang, X. S., Simmons, Z., Liu, W., Boyer, P. J. et al., Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex. Amyotroph. Lateral Scler. 2006, 7, 201-216.
42. Lederer, C. W., Torrisi, A., Pantelidou, M., Santama, N. et al.. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics 2007, 8, 26.
43. Barrett, T., Troup, D. B., Wilhite, S. E., Ledoux, P. et al., NCBI GEO: Mining Tens of millions of expression profiles - Database and tools update. Nucleic Acids Res. 2006, gkl887.
44. Parkinson, H., Kapushesky, M., Shojatalab, M., Abeygunawardena, N. et al., ArrayExpress - a public database of microarray experiments and gene expression profiles. Nucleic Acids Res. 2006, gkl995.
45. Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G. et al., Minimum information about a microarray experiment (MIAME) - Toward standards for microarray data. Nat. Genet. 2001, 29, 365-371.
46. Rao, S. D., Weiss, J. H., Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends Neurosci. 2004, 27, 17-23.
47. Perrin, F. E., Boisset, G., Docquier, M., Schaad, O. et al., No Widespread induction of cell death genes occurs in pure motoneurons in an amyotrophic lateral sclerosis mouse model. Hum. Mol. Genet. 2005, 14, 3309-3320.
48. Blalock, E. M., Geddes, J. W., Chen, K. C., Porter, N. M. et al, Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. USA 2004, 101, 2173-2178.
49. Ramstrom, M., Ivonin, I., Johansson, A., Askmark, H. et al., Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography-fourier transform ion cyclotron resonance mass spectrometry. Proteomics 2004, 4, 4010-4018.
50. Ranganathan, S., Williams, E., Ganchev, P., Gopalakrishnan, V. et al., Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J. Neurochem. 2005, 95, 1461-1471.
51. Pasinetti, G. M., Ungar, L. H., Lange, D. J., Yemul, S. et al., Identification of potential CSF biomarkers in ALS. Neurology 2006, 66, 1218-1222.
52. Kell, D. B., Metabolomics and systems biology: Making sense of the soup. Curr. Opin. Microbiol. 2004, 7, 296-307.
53. Fuchs, F., Boutros, M., Cellular phenotyping by RNAi. Brief Funct. Genomic Proteomic. 2006, 5, 52-56.
54. Mukherji, M., Bell, R., Supekova, L., Wang, Y. et al.. Genome-wide functional analysis of human cell-cycle regulators. Proc. Natl. Acad. Sci. USA 2006, 203, 14819-14824.
55. Julien, J. P., Kriz, J., Transgenic mouse models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2006.
56. Fridovich, I., Superoxide radical and superoxide dismutases. Annu Rev. Biochem. 1995, 64, 97-112.
57. Durham, H. D., Roy, J., Dong, L., Figlewicz, D. A., Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol. 1997, 56, 523-530.
58. Johnston, J. A., Dalton, M. J., Gurney, M. E., Kopito, R. R., Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 2000, 97, 12571-12576.
59. Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L. et al., ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997, 18, 327-338.
60. Shinder, G. A., Lacourse, M. C, Minotti, S., Durham, H. D., Mutant Cu/ Zn-superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis. J. Biol. Chem. 2001, 276, 12791-12796.
61. Shibata, N., Asayama, K., Hirano, A., Kobayashi, M., Immunohisto-chemical study on superoxide dismutases in spinal cords from autopsied patients with amyotrophic lateral sclerosis. Dev. Neurosci. 1996, 18, 492-498.
62. Kato, S., Horiuchi, S., Liu, J., Cleveland, D. W. et al., Advanced glycation endproduct-modified superoxide dismutase-1 (SOD1)-positive inclusions are common to familial amyotrophic lateral sclerosis patients with SOD1 gene mutations and transgenic mice expressing human SOD1 with a G85R mutation. Acta Neuropathol. (Berl) 2000, 100, 490-505.
63. Hoffman, E. K., Wilcox, H. M., Scott, R. W., Siman, R, Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis. J. Neurol. Sci. 1996, 139, 15-20.
64. Kabashi, E., Agar, J. N., Taylor, D. M., Minotti, S. et al., Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2004, 89, 1325-1335.
65. Ciechanover, A., Brundin, P., The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003, 40, 427-446.
66. Kabashi, E., Durham, H. D., Failure of protein quality control in amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2006, 1762, 1038-1050.
67. Cote, F., Collard, J. F., Julien, J. P., Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993, 73, 35-46.
68. Xu, Z., Cork, L. C., Griffin, J. W., Cleveland, D. W., Increased expression of neurofilament subunit nf-1 produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 1993, 73, 23-33.
69. Lee, M. K., Marszalek, J. R., Cleveland, D. W., A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 1994, 13, 975-988.
70. Corbo, M., Hays, A. P., Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. J. Neuropathol. Exp. Neurol. 1992, 51, 531-537.
71. Millecamps, S., Robertson, J., Lariviere, R., Mallet, J. et al., Defective axonal transport of neurofilament proteins in neurons overexpressing peripherin. J. Neurochem. 2006, 98, 926-938.
72. Beaulieu, J. M., Nguyen, M. D., Julien, J. P., Late onset of motor neurons in mice overexpressing wild-type peripherin. J. Cell Biol. 1999, 147, 531-544.
73. Gros-Louis, F., Lariviere, R., Gowing, G., Laurent, S. et al., A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J. Biol. Chem. 2004, 279, 45951-45956.
74. Robertson, J., Doroudchi, M. M., Nguyen, M. D., Durham, H. D. et al., A neurotoxic peripherin splice variant in a mouse model of ALS. J. Cell Biol. 2003, 160, 939-949.
75. Mersiyanova, I. V., Perepelov, A. V., Polyakov, A. V., Sitnikov, V. F. et al., A new variant of charcot-marie-tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am. J. Hum. Genet. 2000, 67, 37-46.
76. De Jonghe P., Mersivanova, I., Nelis, E., Del, F. J. et al., Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann. Neurol. 2001, 49, 245-249.
77. Julien, J. P., A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Biochem. Cell Biol. 1995, 73, 593-597.
78. Collard, J. F., Cote, F., Julien, J. P., Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 1995, 375, 61-64.
79. Jacomy, H., Zhu, Q., Couillard-Despres, S., Beaulieu, J. M. et al., Disruption of type IV intermediate filament network in mice lacking the neurofilament medium and heavy subunits. J. Neurochem. 1999, 73, 972-984.
80. Levavasseur, F., Zhu, Q., Julien, J. P., No requirement of alpha-in-ternexin for nervous system development and for radial growth of axons. Brain Res. Mol. Brain Res. 1999, 69, 104-112.
81. Rao, M. V., Houseweart, M. K., Williamson, T. L., Crawford, T. O. et al., Neurofilament-dependent radial growth of motor axons and axonal organization of neurofilaments does not require the neurofilament heavy subunit (NF-H) or its phosphorylation. J. Cell Biol. 1998, 143, 171-181.
82. Zhu, Q., Lindenbaum, M., Levavasseur, F., Jacomy, H. et al., Disruption of the NF-H gene increases axonal microtubule content and velocity of neurofilament transport: Relief of axonopathy resulting from the toxin beta,beta'-iminodipropionitrile. J. Cell Biol. 1998, 143, 183-193.
83. Eyer, J., Cleveland, D. W., Wong, P. C., Peterson, A. C., Pathogenesis of two axonopathies does not require axonal neurofilaments. Nature 1998, 391, 584-587.
84. Goldstein, L. S., Do disorders of movement cause movement disorders and dementia? Neuron 2003, 40, 415-425.
85. Zhang, B., Tu, P., Abtahian, F., Trojanowski, J. Q. et al., Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J. Cell Biol. 1997, 139, 1307-1315.
86. Williamson, T. L., Cleveland, D. W., Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat. Neurosci. 1999, 2, 50-56.
87. Hurd, D. D., Saxton, W. M., Kinesin mutations cause motor neuron disease phenotypes by disrupting fast axonal transport in Drosophila. Genetics 1996, 144, 1075-1085.
88. Zhao, C., Takita, J., Tanaka, Y., Setou, M. et al., Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 2001, 105, 587-597.
89. Reid, E.,Kloos, M., shley-Koch, A., Hughes, L. et al., A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am. J. Hum. Genet. 2002, 71, 1189-1194.
90. Xia, C. H., Roberts, E. A., Her, L. S., Liu, X. et al., Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J. Cell Biol. 2003, 161, 55-66.
91. LaMonte, B. H., Wallace, K. E., Holloway, B. A., Shelly, S. S. et al., Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002, 34, 715-727.
92. Hafezparast, M., Klocke, R., Ruhrberg, C., Marquardt, A. et al.. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 2003, 300, 808-812.
93. Puls, I., Jonnakuty, C., LaMonte, B. H., Holzbaur, E. L. et al., Mutant dynactin in motor neuron disease. Nat. Genet. 2003, 33, 455-456.
94. Levy, J. R., Sumner, C. J., Caviston, J. P., Tokito, M. K. et al., A motor neuron disease-associated mutation in P150Glued perturbs dynactin function and induces protein aggregation. J. Cell Biol. 2006, 172, 733-745.
95. Kieran, D., Hafezparast, M., Bohnert, S., Dick, J. R. et al., A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J. Cell Biol. 2005, 169, 561-567.
96. Howland, D. S., Liu, J., She, Y., Goad, B. et al., Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. USA 2002, 99, 1604-1609.
97. Gong, Y. H., Parsadanian, A. S., Andreeva, A., Snider, W. D. et al.. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 2000, 20, 660-665.
98. Pramatarova, A., Laganiere, J., Roussel, J., Brisebois, K. et al., Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 2001, 21, 3369-3374.
99. Lino, M. M., Schneider, C, Caroni, P., Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 2002, 22, 4825-4832.
100. Clement, A. M., Nguyen, M. D., Roberts, E. A., Garcia, M. L. et al., Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302, 113-117.
101. Taylor, D. M., Minotti, S., Agar, J. N., Durham, H. D., Overexpression of metallothionein protects cultured motor neurons against oxidative stress, but not mutant Cu/Zn-superoxide dismutase toxicity. Neurotoxicology 2004, 25, 779-792.
102. Siao, C. J., Tsirka, S. E., Tissue plasminogen activator mediates microglial activation via its finger domain through armexin II. J. Neurosci. 2002, 22, 3352-3358.
103. Roth, J., Vogl, T., Sorg, C., Sunderkotter, C., Phagocyte-Specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol. 2003, 24, 155-158.
104. Ling, Q., Jacovina, A. T., Deora, A., Febbraio, M. et al., Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J. Clin. Invest 2004, 313, 38-48.
105. Tsirka, S. E., Tissue plasminogen activator as a modulator of neuronal survival and function. Biochem. Soc. Trans. 2002, 30, 222-225.
106. Viemann, D., Strey, A., Janning, A., Jurk, K. et al., Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 2005, 105, 2955-2962.
107. Broom, W. J., Auwarter, K. E., Ni, J., Russel, D. E. et al., Two approaches to drug discovery in SOD1-mediated ALS. J. Biomol. Screen. 2006, 11, 729-735.
108. Crow, J. P., Calingasan, N. Y., Chen, J., Hill, J. L. et al., Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol. 2005, 58, 258-265.
109. Matthews, R. T., Yang, L., Browne, S., Baik, M. et al., Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA 1998, 95, 8892-8897.
110. Barber, S. C., Mead, R. J., Shaw, P. J., Oxidative Stress in ALS: A mechanism of neurodegeneration and a therapeutic target. Biochim. Biophys. Acta 2006, 1762, 1051-1067.
111. Gurney, M. E., Fleck, T. J., Himes, C. S., Hall, E. D., Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998, 50, 62-66.
112. Andries, M., Van Damme, P., Robberecht, W., Van Den Bosch, L., Ivermectin inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2007, 25, 8-16.
113. Kieran, D., Kalmar, B., Dick, J. R., Riddoch-Contreras, J. et al., Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med. 2004, 10, 402-105.
114. Hivenyi, P., Kiaei, M., Gardian, G., Calingasan, N. Y. et al., Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2004, 88, 576-582.
115. Zhang, W., Narayanan, M., Friedlander, R. M., Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. 2003, 53, 267-270.
116. Wurmser, A. E., Palmer, T. D., Gage, F. H., Neuroscience: Cellular interactions in the stem cell niche. Science 2004, 304, 1253-1255.
117. Nayak, M. S., Kim, Y. S., Goldman, M., Keirstead, H. S. et al., Cellular therapies in motor neuron diseases. Biochim. Biophys. Acta 2006, 1762, 1128-1138.
118. Wichterle, H., Lieberam, I., Porter, J. A., Jessell, T. M., Directed differentiation of embryonic stem cells into motor neurons. Cell 2002, 110, 385-397.
119. Soundararajan, P., Miles, G. B., Rubin, L. L., Brownstone, R. M. et al., Motoneurons derived from embryonic stem cells express transcription factors and develop phenotypes characteristic of medial motor column neurons. J. Neurosci. 2006, 26, 3256-3268.
120. Yan, J., Xu, L., Welsh, A. M., Chen, D. et al., Combined Immuno-suppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells 2006, 24, 1976-1985.
121. Garbuzova-Davis, S., Willing, A. E., Zigova, T., Saporta, S. et al., Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: Distribution, migration, and differentiation. J. Hematother. Stem Cell Res. 2003, 12, 255-270.
122. Chi, L., Ke, Y., Luo, C., Li, B. et al., Motor neuron degeneration promotes neural progenitor cell proliferation, migration, and neurogenesis in the spinal cords of amyotrophic lateral sclerosis mice. Stem Cells 2006, 24, 34-43.
123. Selkirk, S. M., Gene therapy in clinical medicine. Postgrad. Med. J. 2004, 80, 560-570.
124. McCown, T. J., Adeno-associated virus (AAV) vectors in the CNS. Curr. Gene Ther. 2005, 5, 333-338.
125. Flotte, T. R., Adeno-associated virus-based gene therapy for inherited disorders. Pediatr. Res. 2005, 58, 1143-1147.
126. Garrity-Moses, M. E., Teng, Q., Liu, J., Tanase, D. et al., Neuroprotective adeno-associated virus Bcl-XL gene transfer in models of motor neuron disease. Muscle Nerve 2005, 32, 734-744.
127. Kaspar, B. K., Llado, J., Sherkat, N., Rothstein, J. D. et al.. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003, 301, 839-842.
128. Wong, L. F., Goodhead, L., Prat, C., Mitrophanous, K. A. et al., Lentivirus-mediated gene transfer to the central nervous system: Therapeutic and research applications. Hum. Gene Ther. 2006, 17, 1-9.
129. Klein, S. M., Behrstock, S., McHugh, J., Hoffmann, K. et al., GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum. Gene Ther. 2005, 16, 509-521.
130. Storkebaum, E., Lambrechts, D., Dewerchin, M., Moreno-Murciano, M. P. et al., Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 2005, 8, 85-92.
131. Ralph, G. S., Radcliffe, P. A., Day, D. M., Carthy, J. M. et al., Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 2005, 11, 429-433.
132. Weinberg, M. S., Villeneuve, L. M., Ehsani, A., Amarzguioui, M.et al., The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA 2006, 12, 256-262.
133. Takeshima, Y., Yagi, M., Wada, H., Ishibashi, K. et al., Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr. Res. 2006, 59, 690-694.
134. Buckingham, S. D., Esmaeili, B., Wood, M., Sattelle, D. B., RNA interference: From model organisms towards therapy for neural and neuromuscular disorders. Hum. Mol. Genet. 2004, 13, R275-R288.
135. Davis, S., Lollo, B., Freier, S., Esau, C., Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. 2006, 34, 2294-2304.
136. Xia, X., Zhou, H., Huang, Y., Xu, Z., Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis. 2006, 23, 578-586.
137. Turner, M. R., Parton, M. J., Leigh, P. N., Clinical trials in ALS: an overview. Semin. Neurol. 2001, 21, 167-175.
138. Choudry, R. B., Cudkowicz, M. E., Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future. J. Clin. Pharmacol. 2005, 45, 1334-1344.
139. Allen, S., Heath, P. R., Kirby, J., Wharton, S. B. et al., Analysis of the cytosolic proteome in a cell culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defenses, and nitric oxide synthetic pathways. J. Biol. Chem. 2003, 278, 6371-6383.
140. Dass, B., Olanow, C. W., Kordower, J. H., Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology 2006, 66, S89-103.
141. Goodall, E. F., Morrison, K. E., Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert. Rev. Mol. Med. 2006, 8, 1-22.
142. Gong, Y. H., Elliott, J. L., Metallothionein expression is altered in a transgenic murine model of familial amyotrophic lateral sclerosis. Exp. Neurol. 2000, 162, 27-36.
143. Zhu, Q., Couillard-Despres, S., Julien, J. P., Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp. Neurol. 1997, 148, 299-316.
144. Beaulieu, J. M., Jacomy, H., Julien, J. P., Formation of intermediate filament protein aggregates with disparate effects in two transgenic mouse models lacking the neurofilament light subunit. J. Neurosci. 2000, 20, 5321-5328.
145. Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H. et al., Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 2001, 28, 131-138.
146. Cai, H., Lin, X., Xie, C., Laird, F. M. et al., Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knock-out mice but predisposes neurons to oxidative stress. J. Neurosci. 2005, 25, 7567-7574.